Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Septin 14 pseudogene 21 is a genomic region closely resembling the functional gene *Septin 14*, but with disabling mutations (such as frameshifts, premature stop codons, or missing regulatory elements) that prevent its transcription and translation into a functional protein[2][3][4]. Pseudogenes like SEPTIN14P21 may occasionally be transcribed into RNA and, in rare cases, participate in regulation of their parent genes or related pathways, but most are nonfunctional and considered "junk DNA"[1][3][4]. In general, pseudogenes complicate molecular genetic analyses due to their sequence similarity to functional genes, which can cause technical artifacts but do not themselves represent therapeutic targets[4]. There is no evidence SEPTIN14P21 acts as a receptor, enzyme, or other classical drug target, and no data supporting its role in disease or drug interaction. It is best classified simply as a pseudogene[2][3][4].
None (No mechanisms of action are described because it lacks protein-coding ability[3][4])
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Septin 14 pseudogene 21 (SEPTIN14P21).